Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
*Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO upon close and infliximab-abda in Q3 2027*Collaboration combines
